ChromaVision to become Clarient

ChromaVision Medical Systems (San Juan Capistrano, California), a technology and services resource for pathologists, oncologists and the pharmaceutical industry, said that it is changing its name to Clarient "in order to better reflect a new strategy, direction and business plan that have been expanded to serve three distinct markets."

The company expects the name change to be in effect by March 15. It has reserved the ticker symbol CLRT with Nasdaq, and the company's shares are expected to begin trading under that new symbol in mid-March.

CEO Ron Andrews said, "For years, ChromaVision has been creating a disproportionate amount of value for others in the diagnostics field by allowing them to market our imaging technology and expertise Clarient will operate with the mission of capturing that value for the benefit of Clarient shareholders."

Under the Clarient name, the company will be organized into three business units: diagnostic services, which provides a full range of on-site and remote advanced cancer diagnostic testing; biopharmaceutical services, which provides technology to drug companies in pursuit of a new targeted cancer therapies; and the company's legacy imaging equipment product line.

Roche dismisses complaint

Roche Diagnostics (Indianapolis) dismissed a complaint filed in U.S. District Court, Southern District of Indiana on July 30, 2004, against former supplier Access Diabetic Supply (Pompano Beach, Florida).

The lawsuit claimed that Access Diabetic Supply misinformed consumers to believe that the Accu-Chek Compact blood glucose meter had been the subject of a high rate of complaints and product returns and had been recalled. Access Diabetic Supply now has agreed to contact all consumers who may have received the erroneous communication and inform them of the error, Roche said.